Rheumatology International

, Volume 28, Issue 9, pp 895–899 | Cite as

Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study

  • Tim Y. -T. Lu
  • Catherine L. Hill
  • Eliza K. Pontifex
  • Peter J. Roberts-ThomsonEmail author
Original Article


Previous studies have demonstrated an increased risk of breast cancer among patients with systemic sclerosis (scleroderma). To describe the clinical characteristics of 21 patients with both systemic sclerosis and breast cancer, and compare their risk factors to female scleroderma patients without breast cancer, in a population-based cohort study of South Australia. Subjects with scleroderma and breast cancer were identified from the South Australian Scleroderma Register with cross-linking to the South Australian Cancer Registry, last updated to the end of December 2005. Clinical information was obtained from standardised self-administered questionnaires and case note reviews. Odds ratios for the risk factors for breast cancer in scleroderma were determined, and clinical variables were analysed using chi square, Fisher’s exact, Mann–Whitney and t tests. At the end of December 2005 there were a total of 389 female patients with scleroderma. Of these, 21 (5.4%) had been diagnosed with breast cancer. The mean age of onset of scleroderma was 43.5 years, and the mean age of breast cancer was 60.5 years in those with scleroderma and breast cancer. The majority (71.4%) had limited scleroderma, with anti-centromere antibody being the most prevalent serological abnormality. In 16 (76%) patients the diagnosis of breast cancer occurred on an average of 22.3 years after the onset of their first scleroderma symptom. When compared to 48 controls, scleroderma patients with breast cancer were found to have a higher incidence of a positive family history of breast cancer (Fisher’s exact test, p = 0.04) and a lower incidence of hormone-replacement therapy use (Fisher’s exact test, p = 0.0026). This population-based cohort study provides evidence that the majority of patients with scleroderma and breast cancer have limited scleroderma and anti-centromere antibody. Given the increased incidence of solid tumours in systemic sclerosis, we suggest regular screening of female patients for breast cancer, especially in those with a family history.


Systemic sclerosis Breast cancer 


  1. 1.
    Rosenthal AK, McLaughlin JK, Gridley G, Nyren O (1995) Incidence of cancer among patients with systemic sclerosis. Cancer 76:910–914PubMedCrossRefGoogle Scholar
  2. 2.
    Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T (2001) Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 21:106–111PubMedCrossRefGoogle Scholar
  3. 3.
    Launay D, Le Berre R, Hatron PY, Peyrat JP, Hachulla E, Devulder B et al. (2004) Association between systemic sclerosis and breast cancer: eight new cases and review of literature. Clin Rheumatol 23:516–522PubMedCrossRefGoogle Scholar
  4. 4.
    Scope A, Sadetzki S, Sidi Y, Barzilai A, Trau H, Kaufman B et al (2006) Breast cancer and scleroderma. Skinmed 5:18–24PubMedCrossRefGoogle Scholar
  5. 5.
    Hill CL, Nguyen AM, Roder D, Roberts-Thomson PJ (2003) Risk of cancer in patients with scleroderma: a population-based cohort study. Ann Rheum Dis 62:728–731PubMedCrossRefGoogle Scholar
  6. 6.
    Roberts-Thomson PJ, Nikoloutopoulos T, Cox S, Walker JG, Gordon TP (2003) Antinuclear antibody testing in a regional laboratory. Immunol Cell Biol 81:409–412PubMedCrossRefGoogle Scholar
  7. 7.
    Masi AT, Rodnan GP, Medsger TA, Altman RD, D’Angelo WA, Fries JF et al (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRefGoogle Scholar
  8. 8.
    Roberts-Thomson PJ, Jones M, Hakendorf P, Kencana Dharmapatni AASS, Walker JG, MacFarlane JG et al (2001) Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Int Med J 31:220–229CrossRefGoogle Scholar
  9. 9.
    Bonett A, Roder D, Milliken L (1992) The South Australian Cancer Registry: a means of assessing cancer incidence, mortality and case survival. Eur J Cancer 28A:1923–1926PubMedCrossRefGoogle Scholar
  10. 10.
    Derk CT (2007) Associations of breast cancer development in patients with systemic sclerosis: an exploratory study. Clin Rheumatol 26(10):1615–1619 Epub 2 Feb 2007PubMedCrossRefGoogle Scholar
  11. 11.
    Klippel JH, Crofford LJ, Stone JH, Weyand CM (2001) Primer on the rheumatic diseases, 12th edn. Arthritis Foundation Publishing Department, Atlanta, p 353Google Scholar
  12. 12.
    Forbes AM, Woodrow JC, Verbov JL, Graham RM (1989) Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol 28:65–69PubMedCrossRefGoogle Scholar
  13. 13.
    Hasset C, Harnett P, Manolios N (2001) Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol 19:197–200Google Scholar
  14. 14.
    Abu-Shakra M, Guillemin F, Lee P (1993) Cancer in systemic sclerosis. Arthritis Rheum 36:460–464PubMedCrossRefGoogle Scholar
  15. 15.
    Kochhar R, Umbreit JN (2004) Fatal exacerbation of paraneoplastic systemic sclerosis after neoadjuvant chemotherapy in a breast cancer patient. Clin Rheumatol 23:269–271PubMedCrossRefGoogle Scholar
  16. 16.
    Alexandrescu DT, Bhagwati NS, Wiernik PH (2005) Chemotherapy-induced scleroderma: a pleiomorphic syndrome. Clin Dermatol 30:141–145CrossRefGoogle Scholar
  17. 17.
    Querfeld C, Collbeg S, Huerkamp C, Eckes B, Krieg T (2000) Pseudoscleroderma associated with lung cancer: correlation of collagen type 1 and connective tissue growth factor gene expression. Br J Dermatol 142:1128–1133CrossRefGoogle Scholar
  18. 18.
    Askling J (2007) Malignancy and rheumatoid arthritis. Curr Rheumatol Rep 9(5):421–6PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Tim Y. -T. Lu
    • 1
  • Catherine L. Hill
    • 2
  • Eliza K. Pontifex
    • 3
  • Peter J. Roberts-Thomson
    • 3
    Email author
  1. 1.Rheumatology UnitRoyal Adelaide HospitalAdelaideAustralia
  2. 2.Rheumatology UnitThe Queen Elizabeth HospitalAdelaideAustralia
  3. 3.Departments of Immunology, Allergy and ArthritisFlinders Medical CentreAdelaideAustralia

Personalised recommendations